InvestorsHub Logo
Followers 7
Posts 342
Boards Moderated 0
Alias Born 08/12/2022

Re: None

Tuesday, 08/16/2022 7:38:58 AM

Tuesday, August 16, 2022 7:38:58 AM

Post# of 1456
Oncternal Therapeutics Drives Complete Responders with First in Class ROR1 Antagonist The combo with ABBV looks off the charts. Big huge improvements with the combo treatment. 2 distinct drugs in the clinic with ABBV
10 drugs in the pipeline



$ONCT
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCT News